CARM1 and plasma cell myeloma: To exclude the possibility that the decrease in SEs is TP-064-specific, we employed another CARM1-specific inhibitor, EZM2302, which is orally bioavailable, and has been shown to elicit in vivo anti-cancer effects in multiple myeloma (12).